Merck & Co. (MRK) Grants License For HIV/AIDS Drug Efavirenz To South African Company, Thembalami Pharmaceuticals, In Effort To Accelerate Access To Life-Saving Treatment
10/19/2005 5:08:58 PM
Merck & Co., Inc., (the parent company of MSD (Pty) Ltd. South Africa) announced today that it has signed an agreement to grant a non-exclusive patent license for the manufacture and sale of a generic version of efavirenz to Thembalami Pharmaceuticals (Pty) Ltd., a local South African pharmaceutical company. This license covers South Africa and other countries in the Southern African Development Community (SADC), and will apply to both the public and private sectors in these countries. Efavirenz is a non-nucleoside reverse transcriptase inhibitor used in combination therapy for the treatment of HIV infection, sold by MSD under the trademark STOCRIN(R).
comments powered by